MedTrace Logo

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

NCT03616834 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2023-03-22

No results posted yet for this study

Summary

Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.

Conditions

Interventions

DRUG

Tomivosertib (eFT-508)

Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.

Sponsors & Collaborators

  • Effector Therapeutics

    lead INDUSTRY

Principal Investigators

  • Lyon Gleich, MD · Medpace, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-25
Primary Completion
2021-01-31
Completion
2021-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03616834 on ClinicalTrials.gov